Angel Adegbesan

Big Tech stocks created, and have so far dominated, the trillion-dollar club in the U.S. For the first time, there’s a race brewing for an outsider to join their ranks.

For years, investors that poured money into psychedelic stocks have wagered that their breakout moment — and the eye-watering returns that would quickly follow — were just around the corner. And year after year it’s been, by-and-large, a losing bet.

The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs Group Inc. analysts.

Cigna Group could resume its abandoned pursuit of Humana Inc. after the stock prices have moved to the point where a deal makes financial sense, according to Jefferies.

Walgreens Boots Alliance Inc. shares are capping off their worst month in more than five years as the troubled drugstore chain navigates a difficult turnaround that has caused Wall Street to flee the stock.

Share run-ups in Amgen have been short-lived, Mizuho says Detailed data on Amgen's MariTide not expected until year-end

Novavax Inc .'s biggest one-day gain in more than 15 years is forcing some short sellers betting against the stock to exit their positions at a loss.

Novavax Inc.’s biggest one-day gain in more than 15 years is forcing some short sellers betting against the stock to exit their positions at a loss.

Novavax Inc.'s record one-day gain is forcing some short sellers betting against the stock to exit their positions at a loss.

Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.